Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model

During the last two decades, the introduction of tyrosine kinase inhibitors (TKIs) to the therapy has changed the natural history of CML but progression into accelerated and blast phase (AP/BP) occurs in 3-5% of cases, especially in patients resistant to several lines of TKIs. In TKI-refractory pati...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Jusuf Imeri, Paul Marcoux, Matthias Huyghe, Christophe Desterke, Daianne Maciely Carvalho Fantacini, Frank Griscelli, Dimas T. Covas, Lucas Eduardo Botelho de Souza, Annelise Bennaceur Griscelli, Ali G. Turhan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Subjects:	CAR-NK NK92 CD25 leukemia blast crisis CML
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1309010/full